Study design (if review, criteria of inclusion for studies)
randomized cross-over study
Participants
19 CFRD patients.
Interventions
12 weeks each of bedtime NPH or glargine
Outcome measures
fasting plasma glucose with glargine, weight gain
Main results
There was significantly greater reduction in fasting plasma glucose with glargine (P=0.03), and participants showed a non-significant trend towards weight gain with this insulin (P=0.07). No serious hypoglycemia occurred. At study end, all patients chose to continue glargine.
Authors' conclusions
A study of longer duration is needed to determine whether insulin glargine impacts protein catabolism and overall clinical status in CF patients, but these initial data suggest that this is a promising therapy in CFRD.